Health
Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy – News-Medical.net
Avacta Group plc, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co.Ltd and AffyXell Therapeutics.
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. and AffyXell Therapeutics, the joint venture established in South Korea by the two companies, to develop stem cell treatments incorporating Avacta’s neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19 and to also prepare to rapidly develop similar therapies for future globa…
-
Noosa News24 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane
-
General20 hours agoIndia to defend ‘red lines’ as fresh tariffs loom
-
General16 hours agoAlbanese government to freeze construction code until 2029, fast-track housing approvals
-
General21 hours agoCollingwood’s Sarah Rowe returned after just 16 days from collarbone surgery as Magpies beat GWS in AFLW